ReviewOncotarget2015
Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling.
Review in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Surgical outcomes of Adenoid cystic carcinoma treated with Mohs Micrographic Surgery and excision: a systematic review.Archives of dermatological research · 2025Pooled it
- Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors.Cancer medicine · 2025Trial
- A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.Oncotarget · 2017Trial
- Proton Therapy for Head and Neck Adenoid Cystic Carcinoma: A Multi-institutional Review.International journal of particle therapy · 2026Article
- Clinical Outcomes of Dual-Beam Particle Therapy in Head and Neck Adenoid Cystic Carcinoma.Cancers · 2026Article
- Deciphering the potential pathogeny of rare tracheal adenoid cystic carcinoma by single-cell RNA-sequencing.Translational lung cancer research · 2025Article
- Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review).Oncology letters · 2025Review
- Circulating Adenoid Cystic Carcinoma associated MYB transcripts enable rapid and sensitive detection of metastatic disease in blood liquid biopsies.The journal of liquid biopsy · 2024Article
- Circulating Adenoid Cystic Carcinoma associated MYB transcripts enable rapid and sensitive detection of metastatic disease in blood liquid biopsies.medRxiv : the preprint server for health sciences · 2024Article
- Delayed pelvic recurrence in adenoid cystic carcinoma of the Bartholin's gland.Gynecologic oncology reports · 2024Article
- Molecular Aspects of Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Salivary Gland.Head and neck pathology · 2024Review
- Characterization of MYBL1 Gene in Triple-Negative Breast Cancers and the Genes' Relationship to Alterations Identified at the Chromosome 8q Loci.International journal of molecular sciences · 2024Article
- Molecular landscape of salivary gland malignancies. What is already known?Contemporary oncology (Poznan, Poland) · 2024Review
- Prognostic Significance of Histopathological Parameters for Salivary Gland Adenoid Cystic Carcinoma.Dentistry journal · 2023Review
- A novel EWSR1-MYB fusion in an aggressive advanced breast adenoid cystic carcinoma with mixed classical and solid-basaloid components.Virchows Archiv : an international journal of pathology · 2023Article
- Review
- Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review.Diagnostic pathology · 2023Review
- Article
- Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer.Molecules (Basel, Switzerland) · 2023Review
- Rare Case of Primary Adenoid Cystic Carcinoma of the Lung With Bilateral Kidney and Liver Metastasis.Journal of medical cases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Adenoid cystic carcinoma (ACC) is a rare cancer with high potential for recurrence and metastasis. Efficacy of current treatment options, particularly for advanced disease, is very limited. Recent whole genome and exome sequencing has dramatically improved our understanding of ACC pathogenesis. A balanced translocation resulting in the MYB-NFIB fusion gene appears to be a fundamental signature of ACC. In addition, sequencing has identified a number of other driver genes mutated in downstream pathways common to other well-studied cancers. Overexpression of oncogenic proteins involved in cell growth, adhesion, cell cycle regulation, and angiogenesis are also present in ACC. Collectively, studies have identified genes and proteins for targeted, mechanism-based, therapies based on tumor phenotypes, as opposed to nonspecific cytotoxic agents. In addition, although few studies in ACC currently exist, immunotherapy may also hold promise. Better genetic understanding will enable treatment with novel targeted agents and initial exploration of immune-based therapies with the goal of improving outcomes for patients with ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.